Oral squamous cell carcinoma is the most common type of cancer in the oral cavity, representing more than 90% of all oral cancers. The characterization of altered molecules in oral cancer is essential to understand molecular mechanisms underlying tumor progression as well as to contribute to cancer biomarker and therapeutic target discovery. Proteoglycans are key molecular effectors of cell surface and pericellular microenvironments, performing multiple functions in cancer. Two of the major basement membrane proteoglycans, agrin and perlecan, were investigated in this study regarding their role in oral cancer. Using real time quantitative PCR (qRT-PCR), we showed that agrin and perlecan are highly expressed in oral squamous cell carcinoma. Interestingly, cell lines originated from distinct sites showed different expression of agrin and perlecan. Enzymatically targeting chondroitin sulfate modification by chondroitinase, oral squamous carcinoma cell line had a reduced ability to adhere to extracellular matrix proteins and increased sensibility to cisplatin. Additionally, knockdown of agrin and perlecan promoted a decrease on cell migration and adhesion, and on resistance of cells to cisplatin. Our study showed, for the first time, a negative regulation on oral cancer-associated events by either targeting chondroitin sulfate content or agrin and perlecan levels.912 Argiris, A., Karamouzis, M.V., Raben, D., Ferris, R.L., Head and neck cancer (2008) Lancet, 371, pp. 1695-1709Belcher, R., Hayes, K., Fedewa, S., Chen, A.Y., Current treatment of head and neck squamous cell cancer (2014) J Surg OncolMydlarz, W.K., Hennessey, P.T., Califano, J.A., Advances and Perspectives in the Molecular Diagnosis of Head and Neck Cancer (2010) Expert Opin Med Diagn, 4, pp. 53-65Da Silva, S.D., Ferlito, A., Takes, R.P., Brakenhoff, R.H., Valentin, M.D., Advances and applications of oral cancer basic research (2011) Oral Oncol, 47, pp. 783-791Pereira, M.C., Oliveira, D.T., Landman, G., Kowalski, L.P., Histologic subtypes of oral squamous cell carcinoma: Prognostic relevance (2007) J Can Dent Assoc, 73, pp. 339-344Van Kempen, L.C., Ruiter, D.J., Van Muijen, G.N., Coussens, L.M., The tumor microenvironment: A critical determinant of neoplastic evolution (2003) Eur J Cell Biol, 82, pp. 539-548Naba, A., Clauser, K.R., Hoersch, S., Liu, H., Carr, S.A., The matrisome: In silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices (2012) Mol Cell Proteomics, 11, pp. M111+014647Barash, U., Cohen-Kaplan, V., Dowek, I., Sanderson, R.D., Ilan, N., Proteoglycans in health and disease: New concepts for heparanase function in tumor progression and metastasis (2010) FEBS J, 277, pp. 3890-3903Theocharis, A.D., Skandalis, S.S., Tzanakakis, G.N., Karamanos, N.K., Proteoglycans in health and disease: Novel roles for proteoglycans in malignancy and their pharmacological targeting (2010) FEBS J, 277, pp. 3904-3923Iozzo, R.V., Sanderson, R.D., Proteoglycans in cancer biology, tumour microenvironment and angiogenesis (2011) J Cell Mol Med, 15, pp. 1013-1031Edwards, I.J., Proteoglycans in prostate cancer (2012) Nat Rev Urol, 9, pp. 196-206Tatrai, P., Dudas, J., Batmunkh, E., Mathe, M., Zalatnai, A., Agrin, a novel basement membrane component in human and rat liver, accumulates in cirrhosis and hepatocellular carcinoma (2006) Lab Invest, 86, pp. 1149-1160Mundhenke, C., Meyer, K., Drew, S., Friedl, A., Heparan sulfate proteoglycans as regulators of fibroblast growth factor-2 receptor binding in breast carcinomas (2002) Am J Pathol, 160, pp. 185-194Sharma, B., Handler, M., Eichstetter, I., Whitelock, J.M., Nugent, M.A., Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo (1998) J Clin Invest, 102, pp. 1599-1608Savore, C., Zhang, C., Muir, C., Liu, R., Wyrwa, J., Perlecan knockdown in metastatic prostate cancer cells reduces heparin-binding growth factor responses in vitro and tumor growth in vivo (2005) Clin Exp Metastasis, 22, pp. 377-390Iozzo, R.V., Cohen, I.R., Grassel, S., Murdoch, A.D., The biology of perlecan: The multifaceted heparan sulphate proteoglycan of basement membranes and pericellular matrices (1994) Biochem J, 302, pp. 625-639Noonan, D.M., Fulle, A., Valente, P., Cai, S., Horigan, E., The complete sequence of perlecan, a basement membrane heparan sulfate proteoglycan, reveals extensive similarity with laminin A chain, low density lipoprotein-receptor, and the neural cell adhesion molecule (1991) J Biol Chem, 266, pp. 22939-22947Murdoch, A.D., Liu, B., Schwarting, R., Tuan, R.S., Iozzo, R.V., Widespread expression of perlecan proteoglycan in basement membranes and extracellular matrices of human tissues as detected by a novel monoclonal antibody against domain III and by in situ hybridization (1994) J Histochem Cytochem, 42, pp. 239-249Mishra, M., Chandavarkar, V., Naik, V.V., Kale, A.D., An immunohistochemical study of basement membrane heparan sulfate proteoglycan (perlecan) in oral epithelial dysplasia and squamous cell carcinoma (2013) J Oral Maxillofac Pathol, 17, pp. 31-35Ida-Yonemochi, H., Ikarashi, T., Nagata, M., Hoshina, H., Takagi, R., The basement membrane-type heparan sulfate proteoglycan (perlecan) in ameloblastomas: Its intercellular localization in stellate reticulum-like foci and biosynthesis by tumor cells in culture (2002) Virchows Arch, 441, pp. 165-173Ikarashi, T., Ida-Yonemochi, H., Ohshiro, K., Cheng, J., Saku, T., Intraepithelial expression of perlecan, a basement membrane-type heparan sulfate proteoglycan reflects dysplastic changes of the oral mucosal epithelium (2004) J Oral Pathol Med, 33, pp. 87-95Iozzo, R.V., Zoeller, J.J., Nystrom, A., Basement membrane proteoglycans: Modulators Par Excellence of cancer growth and angiogenesis (2009) Mol Cells, 27, pp. 503-513Winzen, U., Cole, G.J., Halfter, W., Agrin is a chimeric proteoglycan with the attachment sites for heparan sulfate/chondroitin sulfate located in two multiple serine-glycine clusters (2003) J Biol Chem, 278, pp. 30106-30114Somoracz, A., Tatrai, P., Horvath, G., Kiss, A., Kupcsulik, P., Agrin immunohistochemistry facilitates the determination of primary versus metastatic origin of liver carcinomas (2010) Hum Pathol, 41, pp. 1310-1319Batmunkh, E., Tatrai, P., Szabo, E., Lodi, C., Holczbauer, A., Comparison of the expression of agrin, a basement membrane heparan sulfate proteoglycan, in cholangiocarcinoma and hepatocellular carcinoma (2007) Hum Pathol, 38, pp. 1508-1515Agostini, M., Almeida, L.Y., Bastos, D.C., Ortega, R.M., Moreira, F.S., The Fatty Acid synthase inhibitor orlistat reduces the growth and metastasis of orthotopic tongue oral squamous cell carcinomas (2014) Mol Cancer Ther, 13, pp. 585-595Aragao, A.Z., Belloni, M., Simabuco, F.M., Zanetti, M.R., Yokoo, S., Novel processed form of syndecan-1 shed from SCC-9 cells plays a role in cell migration (2012) PLoS One, 7, p. e43521Silva, H., Frezard, F., Peterson, E.J., Kabolizadeh, P., Ryan, J.J., Heparan sulfate proteoglycan-mediated entry pathway for charged tri-platinum compounds: Differential cellular accumulation mechanisms for platinum (2012) Mol Pharm, 9, pp. 1795-1802Terp, M.G., Lund, R.R., Jensen, O.N., Leth-Larsen, R., Ditzel, H.J., Identification of markers associated with highly aggressive metastatic phenotypes using quantitative comparative proteomics (2012) Cancer Genomics Proteomics, 9, pp. 265-273Noguti, J., De Moura, C.F., De Jesus, G.P., Da Silva, V.H., Hossaka, T.A., Metastasis from oral cancer: An overview (2012) Cancer Genomics Proteomics, 9, pp. 329-335O'Donnell, R.K., Kupferman, M., Wei, S.J., Singhal, S., Weber, R., Gene expression signature predicts lymphatic metastasis in squamous cell carcinoma of the oral cavity (2005) Oncogene, 24, pp. 1244-1251Chang, K.P., Yu, J.S., Chien, K.Y., Lee, C.W., Liang, Y., Identification of PRDX4 and P4HA2 as metastasis-associated proteins in oral cavity squamous cell carcinoma by comparative tissue proteomics of microdissected specimens using iTRAQ technology (2011) J Proteome Res, 10, pp. 4935-4947Chai, Y.D., Zhang, L., Yang, Y., Su, T., Charugundla, P., Discovery of potential serum protein biomarkers for lymph-node metastasis in oral cancer (2014) Head NeckFeller, L.L.J., Oral Squamous Cell Carcinoma: Epidemiology, Clinical Presentation and Treatment (2012) Journal of Cancer Therapy, 3, pp. 263-268Afratis, N., Gialeli, C., Nikitovic, D., Tsegenidis, T., Karousou, E., Glycosaminoglycans: Key players in cancer cell biology and treatment (2012) FEBS J, 279, pp. 1177-1197Fuster, M.M., Esko, J.D., The sweet and sour of cancer: Glycans as novel therapeutic targets (2005) Nat Rev Cancer, 5, pp. 526-542Vlodavsky, I., Friedmann, Y., Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis (2001) J Clin Invest, 108, pp. 341-347Goldshmidt, O., Zcharia, E., Abramovitch, R., Metzger, S., Aingorn, H., Cell surface expression and secretion of heparanase markedly promote tumor angiogenesis and metastasis (2002) Proc Natl Acad Sci U S A, 99, pp. 10031-10036Pantazaka, E., Papadimitriou, E., Chondroitin sulfate-cell membrane effectors as regulators of growth factor-mediated vascular and cancer cell migration (2014) Biochim Biophys Acta, 1840, pp. 2643-2650Cattaruzza, S., Perris, R., Proteoglycan control of cell movement during wound healing and cancer spreading (2005) Matrix Biol, 24, pp. 400-417Zhou, Z., Wang, J., Cao, R., Morita, H., Soininen, R., Impaired angiogenesis, delayed wound healing and retarded tumor growth in perlecan heparan sulfate-deficient mice (2004) Cancer Res, 64, pp. 4699-4702Whitelock, J.M., Graham, L.D., Melrose, J., Murdoch, A.D., Iozzo, R.V., Human perlecan immunopurified from different endothelial cell sources has different adhesive properties for vascular cells (1999) Matrix Biol, 18, pp. 163-178Klein, G., Conzelmann, S., Beck, S., Timpl, R., Muller, C.A., Perlecan in human bone marrow: A growth-factor-presenting, but anti-adhesive, extracellular matrix component for hematopoietic cells (1995) Matrix Biol, 14, pp. 457-465Bix, G., Iozzo, R.V., Matrix revolutions: Tail of basement-membrane components with angiostatic functions (2005) Trends Cell Biol, 15, pp. 52-60Hayashi, K., Madri, J.A., Yurchenco, P.D., Endothelial cells interact with the core protein of basement membrane perlecan through beta 1 and beta 3 integrins: An adhesion modulated by glycosaminoglycan (1992) J Cell Biol, 119, pp. 945-959Martin, P.T., Sanes, J.R., Integrins mediate adhesion to agrin and modulate agrin signaling (1997) Development, 124, pp. 3909-3917Yip, G.W., Smollich, M., Gotte, M., Therapeutic value of glycosaminoglycans in cancer (2006) Mol Cancer Ther, 5, pp. 2139-2148Zhang, J.S., Anraku, M., Kadowaki, D., Imai, T., Suenaga, A., Spectroscopic studies of interactions of chondroitin sulfates with cisplatin (2011) Carbohydr Res, 346, pp. 631-637Rabik, C.A., Dolan, M.E., Molecular mechanisms of resistance and toxicity associated with platinating agents (2007) Cancer Treat Rev, 33, pp. 9-23Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Molecular mechanisms of cisplatin resistance (2012) Oncogene, 31, pp. 1869-1883Dasari, S., Bernard Tchounwou, P., Cisplatin in Cancer therapy: Molecular mechanisms of action (2014) Eur J PharmacolBarr, M.P., Gray, S.G., Hoffmann, A.C., Hilger, R.A., Thomale, J., Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature (2013) PLoS One, 8, p. e54193Eberle, K.E., Sansing, H.A., Szaniszlo, P., Resto, V.A., Berrier, A.L., Carcinoma matrix controls resistance to cisplatin through talin regulation of NF-kB (2011) PLoS One, 6, p. e21496Teng, P.N., Wang, G., Hood, B.L., Conrads, K.A., Hamilton, C.A., Identification of candidate circulating cisplatin-resistant biomarkers from epithelial ovarian carcinoma cell secretomes (2014) Br J Cancer, 110, pp. 123-132